Abbott announced that the FDA has approved a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new Abbott Vysis ALK Break Apart fluorescence in-situ hybridization (FISH) Probe test is designed to identify ALK-positive NSCLC patients for treatment with Xalkori (crizotinib; Pfizer), an oral first-in-class ALK inhibitor NSCLC therapy.

For more information call (800) 553-7042 or visit